{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:02:18Z","timestamp":1773154938669,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marie Sk\u0142odowska-Curie Actions (MSCA) Innovative Training Networks (ITN): H2020-MSCA-ITN-2019","award":["813343"],"award-info":[{"award-number":["813343"]}]},{"name":"Janssen Vaccines &amp; Prevention, Leiden, The Netherlands","award":["813343"],"award-info":[{"award-number":["813343"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Ad26.COV2.S vaccination can lead to vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but severe adverse effect, characterized by thrombocytopenia and thrombosis. The mechanism of VITT induction is unclear and likely multifactorial, potentially including the activation of platelets and endothelial cells mediated by the vaccine-encoded spike protein (S protein). Here, we investigated the biodistribution of the S protein after Ad26.COV2.S dosing in three animal models and in human serum samples. The S protein was transiently present in draining lymph nodes of rabbits after Ad26.COV2.S dosing. The S protein was detected in the serum in all species from 1 day to 21 days after vaccination with Ad26.COV2.S, but it was not detected in platelets, the endothelium lining the blood vessels, or other organs. The S protein S1 and S2 subunits were detected at different ratios and magnitudes after Ad26.COV2.S or COVID-19 mRNA vaccine immunization. However, the S1\/S2 ratio did not depend on the Ad26 platform, but on mutation of the furin cleavage site, suggesting that the S1\/S2 ratio is not VITT related. Overall, our data suggest that the S-protein biodistribution and kinetics after Ad26.COV2.S dosing are likely not main contributors to the development of VITT, but other S-protein-specific parameters require further investigation.<\/jats:p>","DOI":"10.3390\/vaccines12050559","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T11:06:41Z","timestamp":1716203201000},"page":"559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-0394","authenticated-orcid":false,"given":"Sonia","family":"Marquez-Martinez","sequence":"first","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-1114","authenticated-orcid":false,"given":"Selina","family":"Khan","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan van der","family":"Lubbe","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-6468","authenticated-orcid":false,"given":"Laura","family":"Solforosi","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea M. M.","family":"Costes","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Choi","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Boedhoe","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke","family":"Verslegers","sequence":"additional","affiliation":[{"name":"Janssen Research & Development (JRD), B-2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0852-092X","authenticated-orcid":false,"given":"Marjolein van","family":"Heerden","sequence":"additional","affiliation":[{"name":"Janssen Research & Development (JRD), B-2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7055-5875","authenticated-orcid":false,"given":"Wendy","family":"Roosen","sequence":"additional","affiliation":[{"name":"Janssen Research & Development (JRD), B-2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra De","family":"Jonghe","sequence":"additional","affiliation":[{"name":"Janssen Research & Development (JRD), B-2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8022-6637","authenticated-orcid":false,"given":"Hendy","family":"Kristyanto","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Rezelj","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[{"name":"Janssen Research & Development (JRD), B-2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Tolboom","sequence":"additional","affiliation":[{"name":"Janssen Research & Development (JRD), B-2340 Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-1492","authenticated-orcid":false,"given":"Frank","family":"Wegmann","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-6231","authenticated-orcid":false,"given":"Roland C.","family":"Zahn","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S COVID-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/cid\/ciab465","article-title":"Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients","volume":"74","author":"Ogata","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","unstructured":"Shimabukuro, T.T. (2021). Thrombosis with Thrombocytopenia Syndrome (TTS) following Janssen COVID-19 Vaccine, CDC COVID-19 Vaccine Task Force Vaccine Safety Team."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1016\/j.vaccine.2023.07.013","article-title":"Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S","volume":"41","author":"Struyf","year":"2023","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case Series of Thrombosis with Thrombocytopenia Syndrome after COVID-19 Vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41541-022-00569-8","article-title":"Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination","volume":"7","author":"Buoninfante","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_9","unstructured":"Praet, N. (2022, January 27). Janssen epidemiology activities to characterize the risk of vaccine-induced TTS. Proceedings of the EMA Workshop on Thrombosis with Thrombocytopenia Syndrome, Virtual."},{"key":"ref_10","unstructured":"Chen, R.T. (2021). Updated Brighton Collaboration Case Definition for Thrombosis with Thrombocytopenia Syndrome (TTS), Brighton Collaboration."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","article-title":"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: A global safety database analysis","volume":"398","author":"Bhuyan","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.metop.2021.100101","article-title":"Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story","volume":"11","author":"Tsilingiris","year":"2021","journal-title":"Metabol. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMc2106075","article-title":"Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination\u2014Response from the Manufacturer","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.26542","article-title":"COVID-19 mRNA-1273 vaccine induces production of vaccine-induced immune thrombotic thrombocytopenia antibodies","volume":"97","author":"Padmanabhan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2036556","DOI":"10.1080\/21645515.2022.2036556","article-title":"VITT with inactivated SARS-CoV-2 vaccine\u2014Index case","volume":"18","author":"Devi","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e12750","DOI":"10.1002\/rth2.12750","article-title":"Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination","volume":"6","author":"Hosseinzadeh","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMc2210813","article-title":"Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine","volume":"387","author":"Lane","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jth.15604","article-title":"Thrombosis and thrombocytopenia after HPV vaccination","volume":"20","author":"Johansen","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2021.280154","article-title":"Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines","volume":"107","author":"Michalik","year":"2022","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"van der Neut Kolfschoten, M., Inganas, H., Perez-Peinado, C., da Silva Freire, J.C., Melchers, J.M., van Dijk, N., Przeradzka, M., Kourkouta, E., van Manen, D., and Vellinga, J. (2023). Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine. J. Thromb. Haemost.","DOI":"10.1016\/j.jtha.2023.12.020"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJMc2307721","article-title":"Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies","volume":"389","author":"Warkentin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood.2023022136","article-title":"Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure","volume":"142","author":"Schonborn","year":"2023","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.120.049015","article-title":"Heparin-Induced Thrombocytopenia in Severe COVID-19","volume":"142","author":"Daviet","year":"2020","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101061","DOI":"10.1016\/j.eclinm.2021.101061","article-title":"Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases","volume":"39","author":"Taquet","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_28","unstructured":"Luhn, K. (2022). Janssen Perspective on Clinical and Non-Clinical Aspects of VITT\/TTS MoA, EMA."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1155727","DOI":"10.3389\/fmed.2023.1155727","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: What do we know hitherto?","volume":"10","author":"Roytenberg","year":"2023","journal-title":"Front. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCRESAHA.121.318902","article-title":"SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2","volume":"128","author":"Lei","year":"2021","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1212\/NXI.0000000000200127","article-title":"Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia","volume":"10","author":"Geeraerts","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"728513","DOI":"10.3389\/fimmu.2021.728513","article-title":"Pathogenic Mechanisms of Vaccine-Induced Immune Thrombotic Thrombocytopenia in People Receiving Anti-COVID-19 Adenoviral-Based Vaccines: A Proposal","volume":"12","author":"Azzarone","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_34","unstructured":"(2011). Guide for the Care and Use of Laboratory Animals, The National Academies Press. [8th ed.]. The National Academies Collection: Reports funded by National Institutes of Health."},{"key":"ref_35","unstructured":"U.S. Department of Health and Human Services, and National Institutes of Health Office of Laboratory Animal Welfare (2015). Public Health Service Policy on Humane Care and Use of Laboratory Animals, U.S. Department of Health and Human Services. No. 15-8013."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): Results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zahn, R., Gillisen, G., Roos, A., Koning, M., van der Helm, E., Spek, D., Weijtens, M., Grazia Pau, M., Radosevic, K., and Weverling, G.J. (2012). Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044115"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_41","unstructured":"EMA (2021). Comirnaty, EMA. Assessment report."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-020-20321-x","article-title":"Stabilizing the closed SARS-CoV-2 spike trimer","volume":"12","author":"Juraszek","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/15376510802312464","article-title":"Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer\u2019s construct, or gene inserts","volume":"5","author":"Sheets","year":"2008","journal-title":"J. Immunotoxicol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-021-00301-y","article-title":"Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease","volume":"6","author":"Vijayan","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Khan, S., Marquez-Martinez, S., Erkens, T., de Wilde, A., Costes, L.M.M., Vinken, P., De Jonghe, S., Roosen, W., Talia, C., and Chamanza, R. (2023). Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits. Vaccines, 11.","DOI":"10.3390\/vaccines11121792"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/intimm\/5.6.647","article-title":"Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus","volume":"5","author":"Chen","year":"1993","journal-title":"Int. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Robles, J.P., Zamora, M., Adan-Castro, E., Siqueiros-Marquez, L., Martinez de la Escalera, G., and Clapp, C. (2022). The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin alpha5beta1 and NF-kappaB signaling. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.101695"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"687783","DOI":"10.3389\/fcvm.2021.687783","article-title":"SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity","volume":"8","author":"Raghavan","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"836492","DOI":"10.3389\/fimmu.2022.836492","article-title":"SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19)","volume":"13","author":"Stebbings","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3324\/haematol.2021.280180","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: A possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein","volume":"107","author":"Piscopo","year":"2022","journal-title":"Haematologica"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/5\/559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:45:23Z","timestamp":1760107523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/5\/559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["vaccines12050559"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12050559","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}